Chunhua Yang,1,2 Hang Cao,1 Ning Liu,1 Kai Xu,1 Meng Ding,1 Li-jun Mao1 1Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University, 2Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, People’s Republic of China Abstract: Conditionally replicating adenoviruses have emerged as novel therapeutic agents for cancer. This study aimed to evaluate synergistic antitumor activity of replication-competent adenovirus armed with interleukin (IL)-18 (ZD55-IL-18) and dacarbazine (DTIC) against melanoma. Melanoma A375 cells or nude mouse tumor xenografts were treated with ZD55-IL-18 alone or together with DTIC. The results showed that ZD55-IL-18 competently replicated in A375 cells and exp...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
The oncolytic adenovirus (Ad) is currently being advanced as a promising antitumor remedy as it sele...
Intratumoral immunotherapies are entering clinical use but concerns remain regarding their effects o...
Advanced melanoma is associated with poor prognosis warranting the development of new therapeutics, ...
Melanoma patients with metastases have a very low survival rate and limited treatment options. There...
ONYX-015 is an attractive therapeutic adenovirus for cancer because it can selectively replicate in ...
For long it has been recognized that tumor necrosis factor alpha (TNFa) has anticancer characteristi...
Despite the rapid progress in the development of novel adop-tive T-cell therapies, the clinical bene...
The efficacy of adenovirus-mediated gene therapy for treatment of metastatic B16 melanomas, establis...
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the pa...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Miao Tang,1 Cong Zu,2 Anning He,2 Wenqian Wang,1 Bo Chen,1 Xinyu Zheng1,2 1Department of Breast Sur...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
The oncolytic adenovirus (Ad) is currently being advanced as a promising antitumor remedy as it sele...
Intratumoral immunotherapies are entering clinical use but concerns remain regarding their effects o...
Advanced melanoma is associated with poor prognosis warranting the development of new therapeutics, ...
Melanoma patients with metastases have a very low survival rate and limited treatment options. There...
ONYX-015 is an attractive therapeutic adenovirus for cancer because it can selectively replicate in ...
For long it has been recognized that tumor necrosis factor alpha (TNFa) has anticancer characteristi...
Despite the rapid progress in the development of novel adop-tive T-cell therapies, the clinical bene...
The efficacy of adenovirus-mediated gene therapy for treatment of metastatic B16 melanomas, establis...
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the pa...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Miao Tang,1 Cong Zu,2 Anning He,2 Wenqian Wang,1 Bo Chen,1 Xinyu Zheng1,2 1Department of Breast Sur...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only ...